EXECUTIVE ENGAGEMENTS
POOL
2014
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
363
Interactions with Platform & by Email
PARTICIPANTS
62
Unique # Participated
VALIDATIONS
18
Responses Validated*
COMPANIES
30
Responses Validated*
* Login for a full stack data experience
DATE
APR 2021
TABLES
32
PAGES
92
EDITION
16
PRICE
USD 5450
CODE
MCP-6815
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
Amid the COVID-19 crisis, the global market for Peripheral Arterial Disease (PAD) Therapeutics estimated at US$776.4 Million in the year 2020, is projected to reach a revised size of US$1.1 Billion by 2027, growing at a CAGR of 4.7% over the period 2020-2027.
The Peripheral Arterial Disease (PAD) Therapeutics market in the U.S. is estimated at US$228.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$189.1 Million by the year 2027 trailing a CAGR of 4.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.5% and 3.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.
SELECT PLAYERS
AstraZeneca Plc.; Bayer HealthCare Pharmaceuticals; Bristol-Myers Squibb Company; Merck & Co., Inc.; Proteon Therapeutics, Inc.; Sanofi S.A.; Symic Bio, Inc.; TheraVasc, Inc.
SEGMENTS
» Segment (Peripheral Arterial Disease (PAD) Therapeutics)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| PAD - A Prelude |
| Recent Market Activity |
| PAD Statistics |
| Critical Limb Ischemia - An Insight |
| High Costs - A Cause of Concern |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| AstraZeneca Plc. (UK) |
| Bayer HealthCare Pharmaceuticals (Germany) |
| Bristol-Myers Squibb Company (US) |
| Merck & Co., Inc. (US) |
| Proteon Therapeutics, Inc. (US) |
| Sanofi S.A. (France) |
| Symic Bio, Inc. (US) |
| TheraVasc Inc. (US) |
| 3. MARKET TRENDS & DRIVERS |
| Aging - A Key Driver |
| High Diabetes Incidence Worldwide: Key Market Opportunity for PAD Therapeutics |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| CANADA |
| Canada Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| JAPAN |
| Japan Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| CHINA |
| China Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| EUROPE |
| Europe Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| GERMANY |
| Germany Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| ITALY |
| Italy Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| UNITED KINGDOM |
| UK Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| IV. COMPETITION |
| Total Companies Profiled: 30 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com